NCCN Guidelines® Insights - Primary Cutaneous Lymphomas, Version 2.2020
Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL), and Sézary syndrome (SS) is a rare erythrodermic and leukemic subtype of CTCL characterized by signiﬁcant blood involvement. Although early-stage disease can be effectively treated predominantly with skin-directed therapies, systemic therapy is often necessary for the treatment of advanced-stage disease. Systemic therapy options have evolved in recent years with the approval of novel agents such as romidepsin, brentuximab vedotin, and mogamulizumab. These NCCN Guidelines Insights discuss the diagnosis and management of MF and SS (with a focus on systemic therapy).
This activity is designed to meet the educational needs of oncologists, nurses, pharmacists, and other healthcare professionals who manage patients with cancer.
Upon completion of this activity, participants will be able to:
- Integrate into professional practice the updates to the NCCN Guidelines for Primary Cutaneous Lymphomas
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Primary Cutaneous Lymphomas
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).
Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
The NCCN staff listed below discloses no relevant financial relationships:
Kerrin M. Rosenthal, MA; Kimberly Callan, MS; Genevieve Emberger Hartzman, MA; Erin Hesler; Kristina M. Gregory, RN, MSN, OCN; Rashmi Kumar, PhD; Karen Kanefield; and Kathy Smith.
Individuals Who Provided Content Development and/or Authorship Assistance:
Steven M. Horwitz, MD, Panel Chair, has disclosed that he receives consulting fees from ADCT, Astex, C4 Therapeutics, Celgene, Curio, Janssen, Kura Oncology, Kyowa Hakko Kirin Co., Ltd., Myeloid Therapeutics, Seattle Genetics, Inc, Takeda, and Verastem; and that he receives grant/research support from ADCT, Celgene, Seattle Genetics, Inc, Verastem, Aileron, Corvus, Daichii, Forty-Seven, Portola, and Trillium.
Kristopher Fisher, MD, Panel Member, has disclosed that he has no relevant ﬁnancial relationships.
Aaron M. Goodman, MD, Panel Member, has disclosed that he receives consulting fees from EUSA and Seattle Genetics, Inc.
Gaurav Goyal, MD, Panel Member, has disclosed that he has no relevant ﬁnancial relationships.
Joan Guitart, MD, Panel Member, has disclosed that she is a scientiﬁc advisor for Kyowa Hakko Kirin Co., Ltd., and Miragen; and receives grant/research support from Ecorac, Galderma, Miragen, and Solygenix.
Bradley M. Haverkos, MD, MPH, MS, Panel Member, has disclosed that he receives consulting fees from Viracta Therapeutics.
Richard T. Hoppe, MD, Panel Member, has disclosed that he has no relevant ﬁnancial relationships.
Youn H. Kim, MD, Panel Member, has disclosed that she receives grant/research support from Eisai Inc.; Kyowa Hakko Kirin Co., Ltd.; Merck & Co., Inc.; Corvus; Elorac; Galderma; Horizon; Innate; Soligenix; Trillium; Portola Pharmaceuticals, Inc.; and Seattle Genetics, Inc. She is a scientiﬁc advisor for Kyowa Hakko Kirin Co., Ltd., Corvus, Galderma, Innate, Portola Pharmaceuticals, Inc., Seattle Genetics, Inc., and Takeda Pharmaceuticals North America, Inc.; receives consulting fees from Kyowa Hakko Kirin Co., Ltd., Galderma, Innate, Seattle Genetics, Inc., and Takeda Pharmaceuticals North America, Inc.; and has received honoraria from Kyowa Hakko Kirin Co., Ltd., and Galderma.
Deepa Jagadeesh, MD, MP, Panel Member, has disclosed that she receives grant/research support from Seattle Genetics, Inc., Regeneron Pharmaceuticals, Debiopharm, and MEI Pharma, and that she is a scientiﬁc advisor for Seattle Genetics, Inc., Kyowa Hakko Kirin Co., Ltd., Atara Biotherapeutics, and Verastem.
Neha Mehta-Shah, MD, Panel Member, has disclosed that she has no relevant ﬁnancial relationships.
Elise A. Olsen, MD, Panel Member, has disclosed that she receives consulting fees from Almirall, Aclaris, Helsinn, Incyte, Pﬁzer, Arena, and Cassopea; and that she receives grant/research support from Aclaris, Elorac, and Galderma.
Andrei Shustov, MD, Panel Member, has disclosed that he receives honoraria from Verastem, Inc., and grant/research support from Acrotech, Inc.
Basem M. William, MD, Panel Member, has disclosed that he receives consulting fees from Celgene Corporation, Kyowa Hakko Kirin Co., Ltd., Guidepoint Global, and Techspert; and that he receives grant/research support from Incyte Corporation and Dova.
Mary A. Dwyer, MS, CGC, Director, Guidelines Operations, NCCN, has disclosed that she has no relevant ﬁnancial relationships.
Hema Sundar, PhD, Oncology Scientist/Senior Medical Writer, NCCN, has disclosed that she has no relevant ﬁnancial relationships.
To view all of the conﬂicts of interest for the panel, go to NCCN.org/disclosures/guidelinepanellisting.aspx.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: JA4008196-0000-20-006-H01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until May 10, 2021. PAs should only claim credit commensurate with the extent of their participation.
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation